Aquestive Therapeutics, Inc.
AQST
$5.39
$0.316.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.56% | -7.30% | -22.61% | -26.32% | -24.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.56% | -7.30% | -22.61% | -26.32% | -24.38% |
| Cost of Revenue | 3.83% | 7.22% | 3.82% | -4.39% | -6.64% |
| Gross Profit | 34.48% | -14.00% | -34.52% | -36.00% | -32.54% |
| SG&A Expenses | 22.03% | 22.52% | 59.13% | 44.18% | 53.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.44% | 11.27% | 30.87% | 23.98% | 31.52% |
| Operating Income | -0.27% | -35.72% | -130.90% | -164.37% | -246.29% |
| Income Before Tax | -20.25% | -27.02% | -89.77% | -96.61% | -152.57% |
| Income Tax Expenses | -- | -- | -- | -113.86% | 64.10% |
| Earnings from Continuing Operations | -20.27% | -27.05% | -89.83% | -96.00% | -152.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.27% | -27.05% | -89.83% | -96.00% | -152.89% |
| EBIT | -0.27% | -35.72% | -130.90% | -164.37% | -246.29% |
| EBITDA | -0.40% | -36.63% | -134.69% | -175.49% | -270.86% |
| EPS Basic | 5.86% | -3.31% | -50.11% | -55.71% | -93.41% |
| Normalized Basic EPS | 17.84% | -2.67% | -49.09% | -52.98% | -88.88% |
| EPS Diluted | 5.86% | -3.31% | -50.11% | -55.71% | -93.41% |
| Normalized Diluted EPS | 17.84% | -2.67% | -49.09% | -52.98% | -88.88% |
| Average Basic Shares Outstanding | 27.33% | 23.27% | 23.23% | 22.86% | 27.23% |
| Average Diluted Shares Outstanding | 27.33% | 23.27% | 23.23% | 22.86% | 27.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |